Role of Nanoparticles against Diabetes Mellitus and Cancer

Abstract

According to WHO, there are about 422 million diabetes patients throughout the world. Diabetes Mellitus is a metabolic disorder that results from hyperglycemia due to abnormal secretion and action of insulin. Diabetes is characterized into type 1 diabetes, type 2 diabetes and gestational diabetes. According to the survey of WHO in 2017, there are 3.2 million people suffering from cancer and 8.8 million deaths from cancer around the globe. About 90-95% cancer is due to lifestyle factors. There are six major indications of cancer that required forming a malignant tumor. Treatments based on nanotechnology, such as the creation of nanoscale medication delivery, can enable accurate cancerous tissue targeting while minimizing adverse effects. Nanoparticles can easily overcome cell barriers due to their biological composition. Although numerous treatments can be used to treat tumors, their sensitivity often results in insufficient outcomes and can cause a variety of adverse effects, including damage to normal cells.